NCT03214614View on ClinicalTrials.gov

A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2451 in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

November 14, 2016

Primary Completion Date

August 25, 2017

Study Completion Date

August 25, 2017

Conditions
Healthy
Interventions
DRUG

GLPG2451 multiple dose

GLPG2451 oral suspension, multiple ascending doses, daily for 14 days

DRUG

Placebo multiple dose

Placebo, oral suspension, daily for 14 days

DRUG

GLPG2451/GLPG2222 multiple dose

GLPG2451 oral suspension and GLPG2222 oral suspension, multiple doses, daily for 14 days

DRUG

Combined Placebo multiple dose

Combined Placebo, oral suspension, daily for 14 days

Trial Locations (1)

Unknown

SGS LSS Clinical Pharmacology Unit Antwerp, Antwerp

Sponsors

Lead Sponsor

Galapagos NV
All Listed Sponsors
lead

Galapagos NV

INDUSTRY

NCT03214614 - A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2451 in Healthy Male Subjects | Biotech Hunter | Biotech Hunter